2024
The Alopecia Areata Severity and Morbidity Index (ASAMI) Study
Group A, Moussa A, Bennett M, Wall D, Meah N, York K, Bokhari L, Asfour L, Rees H, Abraham L, Asz-Sigall D, Basmanav F, Bergfeld W, Betz R, Bhoyrul B, Blume-Peytavi U, Callender V, Chitreddy V, Combalia A, Cotsarelis G, Craiglow B, Dhurat R, Donovan J, Doroshkevich A, Eisman S, Farrant P, Ferrando J, Gadzhigoroeva A, Green J, Grimalt R, Harries M, Hordinsky M, Irvine A, Jolliffe V, Kaiumov S, King B, Lee J, Lee W, Li J, Lortkipanidze N, McMichael A, Mesinkovska N, Messenger A, Mirmirani P, Olsen E, Orlow S, Ovcharenko Y, Piraccini B, Pirmez R, Rakowska A, Reygagne P, Rudnicka L, Corralo D, Senna M, Shapiro J, Sharma P, Siliuk T, Starace M, Suchonwanit P, Takwale A, Tosti A, Vañó-Galván S, Visser W, Vogt A, Wade M, Yip L, Zhou C, Sinclair R. The Alopecia Areata Severity and Morbidity Index (ASAMI) Study. JAMA Dermatology 2024, 160: 341-350. PMID: 38324292, DOI: 10.1001/jamadermatol.2023.5869.Peer-Reviewed Original ResearchSurvey roundsTool scorePerspectives of patientsDisease impactDelphi study designHistory of anxietyImpaired quality of lifeQuality of lifeScalp hair lossIdentified various determinantsSeverity of Alopecia Tool scoreAssessment ScaleVideo conference meetingsGlobal Assessment ScaleStudy designImpaired qualitySurvey studyVideo conferencing softwareHair lossSuicidal ideationAA severityConference meetingsAlopecia areataSystemic treatmentDisease duration
2023
41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata
Shapiro J, Ko J, Egeberg A, Somani N, Jedynak J, Torisu-Itakura H, Yu G, Lu N, Craiglow B. 41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata. Journal Of The American Academy Of Dermatology 2023, 89: ab127. DOI: 10.1016/j.jaad.2023.07.511.Peer-Reviewed Original ResearchThe Invisible Impact of a Visible Disease: Psychosocial Impact of Alopecia Areata
Mesinkovska N, Craiglow B, Ball S, Morrow P, Smith S, Pierce E, Shapiro J. The Invisible Impact of a Visible Disease: Psychosocial Impact of Alopecia Areata. Dermatology And Therapy 2023, 13: 1503-1515. PMID: 37289409, PMCID: PMC10307747, DOI: 10.1007/s13555-023-00941-z.Peer-Reviewed Original ResearchPsychological impactEmotional burdenNegative psychological impactGreater psychological impactPoor QoLPsychosocial impactAA symptomsSocial consequencesIllness impactParticipantsIllness characteristicsAnalysis of varianceNational Alopecia Areata FoundationConclusionsThese resultsStigmaQuality of lifeSeverity subgroupsAnxietyOutcome measuresPhysical impactScalp hair lossDepressionQoLAlopecia areataCross-sectional study